Smith & Nephew
About: Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Employees: 17,349
0
Funds holding %
of 7,310 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
70% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 23
15% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 73
8% more capital invested
Capital invested by funds: $827M [Q4 2024] → $891M (+$63.4M) [Q1 2025]
4% more funds holding
Funds holding: 213 [Q4 2024] → 222 (+9) [Q1 2025]
0.26% less ownership
Funds ownership: 3.85% [Q4 2024] → 3.59% (-0.26%) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
89% less call options, than puts
Call options by funds: $14K | Put options by funds: $133K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$28
8%
downside
Avg. target
$28
8%
downside
High target
$28
8%
downside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Canaccord Genuity Caitlin Cronin | 8%downside $28 | Hold Maintained | 1 May 2025 |
Financial journalist opinion
Based on 8 articles about SNN published over the past 30 days
Positive
Zacks Investment Research
1 week ago
SNN Expands Orthopedic Portfolio With Advanced Tibia Nailing System
Smith + Nephew launches TRIGEN MAX, the only tibia nailing system with side-specific nails for precise, low-impact fracture repair.
Positive
Zacks Investment Research
1 week ago
SNN vs. GEHC: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and GE HealthCare Technologies (GEHC). But which of these two stocks is more attractive to value investors?
Positive
Zacks Investment Research
1 week ago
Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Neutral
GlobeNewsWire
1 week ago
Smith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings ‘next-level nailing' to trauma surgeons repairing tibial fractures
The future of fracture fixation with novel side-specific nails featuring variable angle locking technology Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new TRIGEN MAX Tibia Nailing System for stable and unstable fractures of the tibia, including the shaft. It is the only system to now offer trauma surgeons the choice of side-specific (right and left) nails for anatomic screw trajectories, which help to optimize fragment fixation and minimize soft tissue irritation with headless and low-profile screw options.1, 2 The TRIGEN MAX Tibia Nailing System aims to streamline operative procedures and provide efficiency through surgeon-centered design of components and instrumentation, including: Two-piece modular drop system to help when using ancillary instruments and aid visualization.
Neutral
GlobeNewsWire
1 week ago
Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee.
Positive
Zacks Investment Research
1 week ago
Smith+Nephew Stock May Gain From Strategic Deal With Standard Health
SNN teams with Standard Health to launch the United Kingdom's first orthopedic ASC, aiming to boost surgical efficiency and drive growth.
Neutral
GlobeNewsWire
2 weeks ago
Smith+Nephew and Standard Health partner on first Orthopaedic Ambulatory Surgery Centre in the UK
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a strategic partnership with Standard Health www.standardhealth.co.uk to support the development of the first-ever Orthopaedic Ambulatory Surgery Centre in the UK. Based in Poole, Dorset, the new centre will offer NHS and private patients access to leading joint repair and replacement technology for conditions such as rotator cuff repair, ACL reconstruction, knee and hip replacements, and foot & ankle/hand & wrist procedures.
Neutral
GlobeNewsWire
3 weeks ago
New medial stabilized insert for Smith+Nephew's LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatility
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a steep rise in popularity, growing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023.1
Neutral
GlobeNewsWire
1 month ago
Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, has been selected to provide its RENASYS◊ TOUCH Negative Pressure Wound Therapy (NPWT) Systems under a single award, 10-year* contract for up to $75 million by the U.S. Department of Defense (DoD) through the Defense Logistics Agency (DLA).
Neutral
GlobeNewsWire
1 month ago
Study shows patients treated with Smith+Nephew's CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*
The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week
Charts implemented using Lightweight Charts™